BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19...
BC Week In Review | Oct 26, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
BC Extra | Oct 24, 2018
Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
BioCentury | Jun 23, 2018
Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
Items per page:
1 - 4 of 4